This creator highlights Absci as a leader in AI-driven drug discovery, spearheading a historic change in R&D efficiency by compressing timelines and reducing costs. They believe Absci has the potential to become a scaled biotech platform company due to its ability to prosecute programs through to approval and its differentiated approach to both best-in-class and novel biology drug development. The company's active learning loop, combining wet lab data generation with AI models, allows for rapid iteration and increased accuracy in designing antibodies.
“Absci is just really one of the examples where you can very tangibly stick numbers on how much better it is than it was before and you don't need to tip the scales much in favor of efficiency to really have a massive leveraged outcome in the number of drugs approved per billion dollars or what have you so it's very very exciting.”